Tone mix
Week by week 52 weeks
Share of Novartis AG's 978 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Aug 24, 2026 · tone -100Novartis India Ltd Slides 2.56%-141
- Week of Oct 5, 2026 · tone +81Health: Novartis strikes up to $7.8 billion mRNA deal with China's Abogen+92
- Week of Aug 10, 2026 · tone -27Swiss drug applications drop amid Trump's MFN policy (NVS:NYSE)-73
- Week of Oct 12, 2026 · tone +55Novartis FY2027 Earnings Forecast Cut by Erste Group Bank+66
- Week of Dec 29, 2025 · tone 0Destempasidis Calls Novartis 'OPEKEPE of Drugs'-61
- Week of Jan 5, 2026 · tone +5Novartis (NYSE:NVS) Cut to "Hold" at Wall Street Zen-46
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Novartis AG in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 25 | +56 |
| Last 30 sessions | 73 | +35 |
| Last 90 sessions | 331 | +14 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 29, 2026
1 headline, average tone -90: 0 positive, 0 neutral and 1 negative. Showing all 1.
- www.biopharmadive.com · 1 outletLilly shuffles business structure; Novartis writes off part of Avidity dealNegative
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Lilly shuffles business structure; Novartis writes off part of Avidity deal | www.biopharmadive.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 28, 2026
6 headlines, average tone +33: 3 positive, 2 neutral and 1 negative. Showing all 6.
- www.bignewsnetwork.com · 1 outletDepartment of Health - Abu Dhabi, Novartis activate Abu Dhabi Clinical Trials Hub through global phase 3 programmesPositive
- pmlive.com · 1 outletNovartis presents positive results from two phase 3 trials for relapsing MSPositive
- www.proactiveinvestors.com · 1 outletNovartis raises 2026 profit outlook as drug sales offset $1.9 billion impairmentPositive
- www.irishtimes.com · 1 outletNovartis reports $2.2bn hit from drug trial setbacks, but lifts guidanceNegative
- www.fool.com · 1 outletNovartis (NVS) Q3 2026 Earnings Call TranscriptNeutral
- www.investors.com · 1 outletNovartis Hikes Income Forecast, But There Were Caveats Within Its ReportNeutral
Show the table · 6 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Department of Health - Abu Dhabi, Novartis activate Abu Dhabi Clinical Trials Hub through global phase 3 programmes | www.bignewsnetwork.com | 1 | Positive |
| Novartis presents positive results from two phase 3 trials for relapsing MS | pmlive.com | 1 | Positive |
| Novartis raises 2026 profit outlook as drug sales offset $1.9 billion impairment | www.proactiveinvestors.com | 1 | Positive |
| Novartis reports $2.2bn hit from drug trial setbacks, but lifts guidance | www.irishtimes.com | 1 | Negative |
| Novartis (NVS) Q3 2026 Earnings Call Transcript | www.fool.com | 1 | Neutral |
| Novartis Hikes Income Forecast, But There Were Caveats Within Its Report | www.investors.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 27, 2026
6 headlines, average tone +69: 5 positive, 0 neutral and 1 negative. Showing all 6.
- www.rttnews.com · 2 outletsNovartis Q3 Profit Declines; Lifts FY26 Core Income View, Backs Sales OutlookNegative
- econotimes.com · 1 outletNovartis Raises 2026 Core Operating Income Outlook After Q3 GrowthPositive
- www.swissinfo.ch · 1 outletNovartis back on track for growth in third quarterPositive
- www.manilatimes.net · 1 outletNovartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidancePositive
- www.finanznachrichten.de · 1 outletNovartis Pharma AG: Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidancePositive
- finchannel.com · 1 outletNovartis raises core profit outlook despite $1.9 billion impairmentPositive
Show the table · 6 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Novartis Q3 Profit Declines; Lifts FY26 Core Income View, Backs Sales Outlook | www.rttnews.com | 2 | Negative |
| Novartis Raises 2026 Core Operating Income Outlook After Q3 Growth | econotimes.com | 1 | Positive |
| Novartis back on track for growth in third quarter | www.swissinfo.ch | 1 | Positive |
| Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance | www.manilatimes.net | 1 | Positive |
| Novartis Pharma AG: Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance | www.finanznachrichten.de | 1 | Positive |
| Novartis raises core profit outlook despite $1.9 billion impairment | finchannel.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
8 headlines, average tone +72: 7 positive, 0 neutral and 1 negative. Showing all 8.
- www.tickerreport.com · 2 outletsNovartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B OpportunityPositive
- 247wallst.com · 1 outletNovartis (NVS) Drops 3.5% in a Single Session to $150.55Negative
- www.rttnews.com · 1 outletNovartis's Kisqali Shows Six-Year Survival Benefit In Early Breast CancerPositive
- www.finanznachrichten.de · 1 outletNovartis Pharma AG: Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profilePositive
- econotimes.com · 1 outletNovartis Drug Lowers Annualized Relapse Rates by Up to 35.2% in MS TrialsPositive
- econotimes.com · 1 outletNovartis Reports 19.1% Lower Death Risk in Six-Year Kisqali AnalysisPositive
- www.arabnews.com · 1 outletArab News | Novartis' breast cancer drug cuts risk of death by 19 percent after six years, data showsPositive
- www.finanzen.net · 1 outletPress Release: Novartis remibrutinib delivered -3-Positive
Show the table · 8 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity | www.tickerreport.com | 2 | Positive |
| Novartis (NVS) Drops 3.5% in a Single Session to $150.55 | 247wallst.com | 1 | Negative |
| Novartis's Kisqali Shows Six-Year Survival Benefit In Early Breast Cancer | www.rttnews.com | 1 | Positive |
| Novartis Pharma AG: Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile | www.finanznachrichten.de | 1 | Positive |
| Novartis Drug Lowers Annualized Relapse Rates by Up to 35.2% in MS Trials | econotimes.com | 1 | Positive |
| Novartis Reports 19.1% Lower Death Risk in Six-Year Kisqali Analysis | econotimes.com | 1 | Positive |
| Arab News | Novartis' breast cancer drug cuts risk of death by 19 percent after six years, data shows | www.arabnews.com | 1 | Positive |
| Press Release: Novartis remibrutinib delivered -3- | www.finanzen.net | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone +99: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.finanznachrichten.de · 1 outletNovartis Pharma AG: Kisqali shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrencePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Novartis Pharma AG: Kisqali shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Novartis AG, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.